Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

INTRODUCTION: CD4 T regulatory cells (Tregs) are crucial for the maintenance of self-tolerance and are deficient in many common autoimmune diseases such as type 1 diabetes (T1D). Interleukin 2 (IL-2) plays a major role in the activation and function of Tregs and treatment with ultra-low dose (ULD) I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Waldron-Lynch, Frank, Kareclas, Paula, Irons, Kathryn, Walker, Neil M, Mander, Adrian, Wicker, Linda S, Todd, John A, Bond, Simon
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2014
Matèries:
Diabetes and Endocrinology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4054640/
https://ncbi.nlm.nih.gov/pubmed/24898091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005559
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars